VISTIN PHARMA ASA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.9 NOK | -0.83% |
|
+1.70% | +2.58% |
| Mar. 04 | Vistin Pharma ASA (OB:VISTN) acquired 15% stake in CF Pharma Ltd. for ?1.6 million. | CI |
| Feb. 16 | Vistin Pharma ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Sales 2021 | 279M 25.3M | Sales 2022 | 305M 27.69M | Capitalization | 701M 63.63M |
|---|---|---|---|---|---|
| Net income 2021 | 24M 2.18M | Net income 2022 | -4M -363K | EV / Sales 2021 | 2.96 x |
| Net cash position 2021 | 34.36M 3.12M | Net Debt 2022 | 47.73M 4.34M | EV / Sales 2022 | 2.45 x |
| P/E ratio 2021 |
34.6
x | P/E ratio 2022 |
-144
x | Employees | 78 |
| Yield 2021 |
3.87% | Yield 2022 |
4.75% | Free-Float | 45.24% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vistin Pharma ASA
More press releases
| 1 day | -0.83% | ||
| 1 week | +1.70% | ||
| Current month | +7.17% | ||
| 1 month | +5.75% | ||
| 3 months | -1.24% | ||
| 6 months | +0.84% | ||
| Current year | +2.58% |
1 week
22.60
24.30
1 month
21.9024.30
Current year
21.6024.50
1 year
18.6025.10
3 years
11.2527.50
5 years
5.0029.45
10 years
5.0029.45
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 20-02-29 | |
| Director of Finance/CFO | - | 20-03-01 | |
Eivind Egeli
CTO | Chief Tech/Sci/R&D Officer | - | 15-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 76 | 20-05-31 | |
| Director/Board Member | 62 | 15-03-05 | |
| Director/Board Member | 60 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 23.9 | -0.83% | 20,861 |
| 24-04-18 | 24.1 | +0.42% | 12,594 |
| 24-04-17 | 24 | +0.42% | 20,502 |
| 24-04-16 | 23.9 | +3.91% | 3,439 |
| 24-04-15 | 23 | -2.13% | 15,720 |
Real-time Oslo Bors, April 19, 2024 at 10:45 am EDT
More quotes
Vistin Pharma ASA is a Norway-based holding company, which operates through its subsidiary Vistin Pharma AS. The Company is engaged in the pharmaceuticals industry. The Company is a producer and supplier of Active Pharmaceutical Ingredients (APIs), which are used in medications for diabetes. Vistin Pharma offering such products: Metformin HCl (API); Metformin DC (direct compressible granules); Customized Particle Distribution (PSD) and Premix (Metformin + MgSt, can be delivered on-request). The Companyâs customers are pharmaceutical companies worldwide.
Sector
Pharmaceuticals
Calendar
2024-04-23
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +2.58% | 96.97M | |
| +20.91% | 43.54B | |
| +16.96% | 21.74B | |
| +9.05% | 13.53B | |
| +7.98% | 13.02B | |
| +33.80% | 11.28B | |
| -11.05% | 6.99B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.64% | 5.09B |
- Stock Market
- Equities
- VISTN Stock
